Target product selection - where can Molecular Pharming make the difference?

  title={Target product selection - where can Molecular Pharming make the difference?},
  author={Mathew Paul and Audrey Y-H Teh and Richard M Twyman and Julian K-C Ma},
  journal={Current pharmaceutical design},
  volume={19 31},
Four major developments have taken place in the world of Molecular Pharming recently. In the USA, the DARPA initiative challenged plant biotechnology companies to develop strategies for the large-scale manufacture of influenza vaccines, resulting in a successful Phase I clinical trial; in Europe the Pharma-Planta academic consortium gained regulatory approval for a plant-derived monoclonal antibody and completed a first-in-human phase I clinical trial; the Dutch pharmaceutical company Synthon… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-10 of 15 extracted citations


Publications referenced by this paper.
Showing 1-10 of 77 references

Process of transfecting plants

  • A Giritch, Y Symonenko, S Hahn
  • European patent EP2418283; Feb
  • 2012
1 Excerpt

Recombinant carrier molecule for expression, delivery and purification of target polypeptides

  • VM Yusibov, V Mett, K. Musiychuk
  • United States patent US8173408,
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…